Can the Ava fertility tracker device detect early signs of COVID-19?

Defining the role of a fertility bracelet for early recognition and monitoring of COVID-19 in Liechtenstein: an observational study (COVI-GAPP)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN51255782

Enrollment

2170

Registered

2020-04-14

Start date

2020-04-14

Completion date

Unknown

Last updated

2022-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations

Interventions

In a first phase, participants (n=2170) of the population-based GAPP study (https://doi.org/10.4414/smw.2013.13728) will be contacted to be recruited for the COVI-GAPP study. After a first phase of i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Resident in Liechtenstein 2. Aged 35-51 years

Exclusion criteria

Exclusion criteria: 1. Aged under 18 years 2. Inability to provide informed consent

Design outcomes

Primary

Measure	Time frame
Occurrence of COVID-19 infection, as assessed by clinical signs, serology and/or RT-PCR testing. Date of occurrence, clinical symptoms and laboratory results will be collected. The endpoints will be collected by periodic monthly reports obtained on questioning the study participants. Participants and the treating healthcare institutions will be contacted to obtain respective information.	—

Secondary

Measure	Time frame
1. Severity of COVID-19 infection assessed using the following outcome measures. Participants and the treating healthcare institutions will be contacted to obtain respective information. 1.1. Hospitalization needed within 30 days of COVID-19 diagnosis (including timing) 1.2. ICU admission within 30 days of COVID-19 diagnosis (including timing) 1.3. Use of mechanical ventilation within 30 days of COVID-19 diagnosis (including timing) 1.4. Participant-reported health status up to 60 days after COVID-19 diagnosis (including timing) 1.5. COVID-19-related mortality up to 60 days after COVID-19 diagnosis (including timing) 1.6. Viral load assessed using quantitative RT-PCR at onset of clinical symptoms compatible with COVID-19 1.7. Quantitative immunoassay results of COVID-19-specific laboratory markers (including timing) 1.8. Presence of other respiratory pathogens in COVID-19-negative participants if available at 60 days after clinical symptoms (including timing) 1.9. Further healthcare contact of patients tested negative for COVID-19 up to 60 days after symptoms compatible with COVID-19 (including timing)	—

Measure

Time frame

1. Severity of COVID-19 infection assessed using the following outcome measures. Participants and the treating healthcare institutions will be contacted to obtain respective information. 1.1. Hospitalization needed within 30 days of COVID-19 diagnosis (including timing) 1.2. ICU admission within 30 days of COVID-19 diagnosis (including timing) 1.3. Use of mechanical ventilation within 30 days of COVID-19 diagnosis (including timing) 1.4. Participant-reported health status up to 60 days after COVID-19 diagnosis (including timing) 1.5. COVID-19-related mortality up to 60 days after COVID-19 diagnosis (including timing) 1.6. Viral load assessed using quantitative RT-PCR at onset of clinical symptoms compatible with COVID-19 1.7. Quantitative immunoassay results of COVID-19-specific laboratory markers (including timing) 1.8. Presence of other respiratory pathogens in COVID-19-negative participants if available at 60 days after clinical symptoms (including timing) 1.9. Further healthcare contact of patients tested negative for COVID-19 up to 60 days after symptoms compatible with COVID-19 (including timing)

—

Countries

Liechtenstein

Contacts

Public ContactLorenz Risch

lorenz.risch@risch.ch+41 585233000

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 12, 2026